검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Gemcitabine/Cisplatin II (Gemcitabine/Cisplatin II) Merck Sharp & Dohme LLC·Muscle Invasive Bladder Urothelial… ORR 72% |
|---|---|
Overview Program | Gemcitabine/Cisplatin II |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ADC |
Overview Target | Muscle Invasive Bladder Urothelial Carci |
Overview Indication | Muscle Invasive Bladder Urothelial Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | Targeting the angiogenic fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling pathway |
MoA Biomarker | PD-1), and gemcitabine-cisplatin for four to six cycles, follow |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | thrombocytopenia, the incidence was significantly lower in the NC group compared to the GC group |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 72% |
Clinical ORR | 72% |
Clinical Result source | ClinicalTrials.gov NCT00234494 |
Clinical Data Tier / Score | A · 52 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Gemcitabine/Cisplatin II (Gemcitabine/Cisplatin II) Merck Sharp & Dohme LLC·Muscle Invasive Bladder Urothelial… ORR 72% |
|---|---|
Overview Program | Gemcitabine/Cisplatin II |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ADC |
Overview Target | Muscle Invasive Bladder Urothelial Carci |
Overview Indication | Muscle Invasive Bladder Urothelial Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | Targeting the angiogenic fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling pathway |
MoA Biomarker | PD-1), and gemcitabine-cisplatin for four to six cycles, follow |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | thrombocytopenia, the incidence was significantly lower in the NC group compared to the GC group |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 72% |
Clinical ORR | 72% |
Clinical Result source | ClinicalTrials.gov NCT00234494 |
Clinical Data Tier / Score | A · 52 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교